-
Biotech company Tempest surged nearly 4,000%! The latest data confirms the positive results of liver cancer therapy
[Biotech company Tempest skyrocketed 3,972%! New data confirms positive results for liver cancer therapy] On Wednesday, Tempest Therapeutics, Inc., a clinical-stage oncology company. Shares surged 3,9 ... -
Prelude Therapeutics与默沙东开展临床合作 评估PRT3789与KEYTRUDA的联用效果
7月9日，临床阶段的精准肿瘤学公司Prelude Therapeutics宣布与默沙东公司签署了一项临床试验合作与供应协议。根据协议条款，2期临床研究将评估PRT3789与默沙东公司的抗PD-1肿瘤免疫疗法KEYTRUDA联合治疗SMARCA4 ... -
Clinical collaboration between Prelude Therapeutics and MSD to evaluate the combined effect of PRT3789 and KEYTRUDA
On July 9th, Prelude Therapeutics, a precision oncology company in the clinical stage, announced the signing of a clinical trial cooperation and supply agreement with MSD. According to the terms of t ... -
Prelude Therapeuticsとムシャドンの臨床協力によるPRT 3789とKEYTRUDAの併用効果の評価
7月9日、臨床段階の正確な腫瘍学会社Prelude Therapeuticsはマーサドン社と臨床試験協力と供給協定に署名したと発表した。合意条項に基づいて、2期臨床研究はPRT 3789とマーサドン社の抗PD-1腫瘍免疫療法KEYTRUDAが ...- jj13154197690
- 2024-7-9
- サポート
- に反対
- 返信
- コレクション
-
Prelude Therapeutics, 머샤돔과 PRT3789와 KEYTRUDA의 연계 효과 평가 임상 협력
7 월 9 일, 임상 단계의 정확한 종양학 회사 인 Prelude Therapeutics는 Mushadong과 임상 시험 협력 및 공급 계약을 체결했다고 발표했습니다.계약 조항에 따라 임상 2상 연구는 PRT3789와 머샤 동사의 항PD-1 종 ...